Cipla is in talks with a slew of global pharma heavyweights to strike supply pacts for its CFC (choloroflurocarbons) free inhalers on a long-term basis. CFC free inhalers, with an estimated market potential of $3 billion world over, tops the long-term growth prescription penned by the company.
Sources told FE that the company is in talks with at least three global pharma cos such as Pfizer, GSK and the German drug maker Boehninger Ingelheim to enter into long-term supply contracts for its CFC free inhalers for different markets. The talks are in the nascent stage and any deal is expected only after a couple of quarters from now, sources said. However, analysts said that much on this front hinges on the company getting necessary approvals from the drug regulators of different countries, many of which are pending for some time.
?CFC free inhalers will be one of the key drivers for Cipla’s growth in the coming quarters, said Sushant Dalmia, pharma analyst at Angel Broking.